Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Li Zhang, Jianya Zhou et al.|The Lancet Respiratory Medicine|2019Cited by 139
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Li Zhang, Jie Huang et al.|Journal of Thoracic Oncology|2021Cited by 44
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA studyShun Lü, Weiguo Su, Jianxing He et al.|Lung Cancer|2020Cited by 21
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory <i>ALK</i> ‐positive NSCLC from a phase II studyJing Zheng, Li Zhang, Tao Wang et al.|癌症：英文版|2024Cited by 9
Abstract 2997: Longitudinal circulating tumor DNA (ctDNA) analysis predicts response and reveals the resistance mechanisms of ensartinib in ALK+ NSCLC patients (pts) progressed on crizotinib: Updated analysis of a phase II clinical trialYunpeng Yang, Li Zhang, Jie Huang et al.|Cancer Research|2020Cited by 4